Patents by Inventor Federico C. A. Gaeta

Federico C. A. Gaeta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11701374
    Abstract: 8-Hydroxy quinoline derivative compounds for enhancing telomerase reverse transcriptase (TERT) expression, and methods for using the same, are provided. These compounds and methods find use in a variety of applications in which increased expression of telomerase reverse transcriptase is desired.
    Type: Grant
    Filed: May 18, 2011
    Date of Patent: July 18, 2023
    Assignee: Sierra Sciences, Inc.
    Inventors: William H. Andrews, Lancer K. Brown, Laura A. Briggs, Federico C. A. Gaeta, Hamid Mohammadpour, Mieczyslaw A. Piatyszek
  • Patent number: 9732376
    Abstract: A sample collection device having a sample tube, funnel, and cap having a capsule and a piercing insert, the capsule having a stabilization solution. After depositing the sample into the tube via the funnel, the cap is screwed onto the tube, piercing the capsule and releasing the stabilization fluid into the tube. The device can be used at home without clinicial supervision for collecting a saliva sample and transporting the sample to an analysis location for DNA analysis.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: August 15, 2017
    Assignee: ANCESTRY.COM DNA, LLC.
    Inventors: Benjamin J. Oyler, Kenneth G. Chahine, Catherine Ann Ball, Federico C. A. Gaeta
  • Publication number: 20150056716
    Abstract: A sample collection device having a sample tube, funnel, and cap having a capsule and a piercing insert, the capsule having a stabilization solution. After depositing the sample into the tube via the funnel, the cap is screwed onto the tube, piercing the capsule and releasing the stabilization fluid into the tube. The device can be used at home without clinicial supervision for collecting a saliva sample and transporting the sample to an analysis location for DNA analysis.
    Type: Application
    Filed: July 31, 2014
    Publication date: February 26, 2015
    Inventors: Benjamin J. Oyler, Kenneth G. Chahine, Catherine Ann Ball, Federico C.A. Gaeta
  • Patent number: 8119657
    Abstract: Enantiomerically pure (S)-2-amino-1-(2-isopropylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one, (S)-AV1013, is a candidate therapeutic for treating neuropathic pain, addiction behavior and drug withdrawal symptoms. Also described are methods for preparing and using (S)-AV1013, its pharmaceutically acceptable salts as well as pharmaceutically acceptable formulations of the same.
    Type: Grant
    Filed: June 22, 2010
    Date of Patent: February 21, 2012
    Assignee: MediciNova, Inc.
    Inventors: Kirk W. Johnson, Matthew I. Gross, Federico C. A. Gaeta
  • Publication number: 20110039873
    Abstract: The substituted pyrazolo[1,5-a]pyridine compounds in accordance with Formula 1 are strong inhibitors of phosphodiesterase and c-Jun N-terminal kinase activity. Accordingly, Formula 1 compounds are candidate therapeutics for treating disease states such as cancer, neuropathic pain, inflammation as well as cognitive disorders such as Parkinson's Disease.
    Type: Application
    Filed: June 8, 2010
    Publication date: February 17, 2011
    Inventors: Federico C.A. GAETA, Kirk W. JOHNSON, Matthew I. GROSS, Annemarie LEDEBOER
  • Publication number: 20100324082
    Abstract: Enantiomerically pure (S)-2-amino-1-(2-isopropylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one, (S)-AV1013, is a candidate therapeutic for treating neuroathic pain, addiction behavior and drug withdrawal symptoms. Also described are methods for preparing and using (S)-AV1013, its pharmaceutically acceptable salts as well as pharmaceutically acceptable formulations of the same.
    Type: Application
    Filed: June 22, 2010
    Publication date: December 23, 2010
    Inventors: Kirk W. Johnson, Matthew I. Gross, Federico C.A. Gaeta
  • Patent number: 7824849
    Abstract: The invention provides dendritic cell (DC) preparations that present a telomerase reverse transcriptase (TRT) peptide in the context of an MHC class I or MHC class II molecule. The DCs may be pulsed with a TRT polypeptide, or may comprise a recombinant polynucleotide encoding TRT. The invention also describes the use of such compositions for the prevention and treatment of cancers and other diseases.
    Type: Grant
    Filed: April 27, 2006
    Date of Patent: November 2, 2010
    Assignee: Geron Corporation
    Inventor: Federico C. A. Gaeta
  • Patent number: 7732146
    Abstract: Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.
    Type: Grant
    Filed: July 15, 2005
    Date of Patent: June 8, 2010
    Assignee: Avanir Pharmaceuticals
    Inventors: Federico C. A. Gaeta, Andrew Baird, Jerry Anchin, Wenbin Ying, Robert Florkiewicz, Jagadish Sircar, Sunil Kumar K.C.
  • Publication number: 20100035920
    Abstract: The present invention is directed to substituted pyrazolo[1,5-a]pyridines and related methods for their synthesis and use.
    Type: Application
    Filed: August 31, 2009
    Publication date: February 11, 2010
    Applicant: Avigen, Inc.
    Inventors: Federico C.A. Gaeta, Matthew Gross, Kirk W. Johnson
  • Publication number: 20090318437
    Abstract: The present invention is directed to substituted pyrazolo[1,5-a]pyridines and related methods for their synthesis and use.
    Type: Application
    Filed: June 10, 2009
    Publication date: December 24, 2009
    Inventors: Federico C.A. Gaeta, Matthew Gross, Kirk W. Johnson
  • Patent number: 7622256
    Abstract: Methods of antagonizing MIF activity using ibudilast are described. Also described are methods of screening for MIF antagonists. These agents can be used for treating addictions, including drug and behavioral addictions, as well as for treating neuropathic pain.
    Type: Grant
    Filed: May 29, 2007
    Date of Patent: November 24, 2009
    Assignee: Avigen, Inc.
    Inventors: Kirk W. Johnson, Sharmila Vijay, Matthew Gross, Federico C. A. Gaeta
  • Patent number: 7585875
    Abstract: The present invention is directed to substituted pyrazolo[1,5-a]pyridines and related methods for their synthesis and use.
    Type: Grant
    Filed: June 6, 2007
    Date of Patent: September 8, 2009
    Assignee: Avigen, Inc.
    Inventors: Federico C. A. Gaeta, Matthew Gross, Kirk W. Johnson
  • Publication number: 20090221629
    Abstract: Methods of antagonizing MIF activity using ibudilast are described. Also described are methods of screening for MIF antagonists. These agents can be used for treating addictions, including drug and behavioral addictions, as well as for treating neuropathic pain.
    Type: Application
    Filed: May 7, 2009
    Publication date: September 3, 2009
    Inventors: Kirk W. Johnson, Sharmila Vijay, Matthew Gross, Federico C.A. Gaeta
  • Publication number: 20090143451
    Abstract: Compounds, and methods of using the same, are provided which increase the expression of telomerase reverse transcriptase (TERT) in a cell. These compounds and methods find use in a variety of applications in which increased expression of telomerase is desired, including immortalization of cell lines and treating conditions in a subject characterized by cellular senescence.
    Type: Application
    Filed: November 13, 2008
    Publication date: June 4, 2009
    Inventors: William H. Andrews, Laura A. Briggs, Christopher A. Foster, Lancer K. Brown, Mieczyslaw A. Piatyszek, Federico C.A. Gaeta, Munirathnam Chaguturu, Jian Zhang, Tom Kerley
  • Patent number: 7514225
    Abstract: Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.
    Type: Grant
    Filed: July 15, 2005
    Date of Patent: April 7, 2009
    Assignee: Avanir Pharmaceuticals
    Inventors: Federico C. A. Gaeta, Andrew Baird, Jerry Anchin, Wenbin Ying, Robert Florkiewicz, Jagadish Sircar, Sunil Kumar K. C.
  • Patent number: 7435737
    Abstract: Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.
    Type: Grant
    Filed: December 7, 2006
    Date of Patent: October 14, 2008
    Assignee: Avanir Pharmaceutials
    Inventors: Federico C. A. Gaeta, Andrew Baird, Jerry Anchin, Wenbin Ying, Robert Florkiewicz, Jagadish Sircar, Sunil Kumar K. C.
  • Patent number: 7432374
    Abstract: Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.
    Type: Grant
    Filed: March 16, 2007
    Date of Patent: October 7, 2008
    Assignee: Avanir Pharmaceuticals
    Inventors: Federico C. A. Gaeta, Andrew Baird, Jerry Anchin, Wenbin Ying, Robert Florkiewicz, Jagadish Sircar, Sunil Kumar K. C.
  • Patent number: 7402307
    Abstract: The invention provides a method for activating a T lymphocyte by contacting the T lymphocyte with a dendritic cell (DC) that presents a telomerase reverse transcriptase (TRT) peptide in the context of an MHC class I or MHC class II molecule. The DC may be pulsed with a TRT polypeptide or may comprise a recombinant polynucleotide encoding a TRT such as hTRT. The invention also provides DCs comprising a recombinant TRT polynucleotide. The methods and compositions of the invention are used in prevention and treatment of cancers and other cell proliferation diseases or conditions.
    Type: Grant
    Filed: July 30, 2002
    Date of Patent: July 22, 2008
    Assignee: Geron Corporation
    Inventor: Federico C. A. Gaeta
  • Patent number: 7238809
    Abstract: Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.
    Type: Grant
    Filed: May 2, 2006
    Date of Patent: July 3, 2007
    Assignee: Avanir Pharmaceuticals
    Inventors: Federico C. A. Gaeta, Andrew Baird, Jerry Anchin, Wenbin Ying, Robert Florkiewicz, Jagadish Sircar, Sunil Kumar K. C.
  • Patent number: 7235565
    Abstract: Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.
    Type: Grant
    Filed: May 2, 2006
    Date of Patent: June 26, 2007
    Assignee: Avanir Pharmaceuticals
    Inventors: Federico C. A. Gaeta, Andrew Baird, Jerry Anchin, Wenbin Ying, Robert Florkiewicz, Jagadish Sircar, Sunil Kumar K.C.